[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336919-105":59,"doc-detail-336919-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cancer-vaccines-recent-insights-and-future-directions","Cancer Vaccines: Recent Insights and Future Directions","","Cancer Vaccines: Recent Insights and Future Directions reviews progress in cancer immunotherapy, emphasizing mRNA-based vaccines that generate de novo T cell responses against tumor-specific antigens (TSAs). It discusses remaining constraints, including limited availability of immunogenic neoepitopes, driving exploration of tumor-associated antigens (TAAs) and broader strategies. The review highlights human endogenous retroviruses (HERVs) as alternatives capable of inducing both T cell and B cell responses. It also outlines how shared antigen presentation may support efficacy and how vaccines could expand benefit to more tumors and stages.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cancer-vaccines-recent-insights-and-future-directions/336919/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cancer-vaccines-recent-insights-and-future-directions/336919.png","ImageObject",300,407,{"name":92,"@type":93},"Sage","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main focus of the review on cancer vaccines?","Question",{"text":112,"@type":113},"The review assesses the status and limitations of TSA-directed mRNA cancer vaccines and summarizes lessons relevant to developing TAA vaccines, including insights from checkpoint inhibitor studies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why are neoantigens both promising and challenging for personalized immunotherapy?",{"text":117,"@type":113},"Neoantigens can enable personalized immunotherapies because of their tumor specificity and immunogenicity, but research is still driven by the scarcity of immunogenic neoepitopes.",{"name":119,"@type":110,"acceptedAnswer":120},"How do HERVs fit into alternative vaccine strategies mentioned in the review?",{"text":121,"@type":113},"Human endogenous retroviruses are presented as potential alternatives to tumor neoantigens due to high tumoral expression and their ability to elicit T cell reactivity and B cell responses linked to efficacy of existing immunotherapies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336919,1790145695,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Review  \nCancer Vaccines: Recent Insights and Future Directions  \nAretia-Teodora Malacopol 1 and Peter Johannes Holst 1,2, *  \nCitation: Malacopol, A.-T.; Holst, P.J.  \nCancer Vaccines: Recent Insights and Future Directions. Int. J. Mol. Sci. 2024, 25, 11256. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/ijms252011256](10.3390/ijms252011256)  \nAcademic Editor: Laura Masuelli  \nReceived: 11 September 2024  \nRevised: 13 October 2024  \nAccepted: 14 October 2024  \nPublished: 19 October 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 HERVOLUTION Therapeutics, Copenhagen Bio Science (COBIS), 215 Nordre Fasanvej, DK2200 Copenhagen, Denmark; [tmalacopol@hervolutiontx.com](tmalacopol@hervolutiontx.com)  \n2 Department of Biomedical Sciences, The Panum Institute, University of Copenhagen, DK2200 Copenhagen, Denmark  \n* [Correspondence: pholst@hervolutiontx.com](Correspondence: pholst@hervolutiontx.com)  \nAbstract: The field of cancer immunotherapy has seen incredible advancements in the past decades. mRNA-based cancer vaccines generating de novo T cell responses, particularly against tumor-specific antigens (TSAs), have demonstrated promising clinical outcomes and overcome diverse challenges. Despite the high potential of neoantigens to provide personalized immunotherapies through their tumor specificity and immunogenicity, challenges related to the scarcity of immunogenic neoepitopes have prompted continuous research towards finding new tumor-associated antigens (TAAs) and broader therapeutic frameworks, which may now learn from the genuine successes obtained with neoantigens. As an example, human endogenous retroviruses (HERVs) have emerged as potential alternatives to tumor neoantigens due to their high tumoral expression and ability to elicit both T cell reactivity and B cell responses associated with the efficacy of existing immunotherapies. This review aims to assess the status and limitations of TSA-directed mRNA cancer vaccines and the lessons that can be derived from these and checkpoint inhibitor studies to guide TAA vaccine development. We expect that shared B cell, CD4 and CD8 T cell antigen presentation will be key to stimulate continuous T cell expansion and efficacy for tumors that do not contain pre-existing tertiary lymphoid structures. When these structures are present in highly mutated tumors, the current checkpoint-based immunotherapies show efficacy even in immune privileged sites, and vaccines may hold the key to broaden efficacy to more tumor types and stages.  \nKeywords: cancer vaccines; immune system; tumor-specific antigens; neoantigens; checkpoint inhibitors; HERVs  \n1. Introduction  \n1.1. Breakthroughs in the Cancer Vaccine Field  \nThe last 1–2 years have yielded important breakthroughs in cancer vaccination, proving the ability of active immunization with defined recombinant antigens to yield clinically meaningful improvements in patient outcomes. Notably, the three-year Phase 1 follow-up from BioNTech’s neoantigen individualized mRNA vaccine (autogene cevumeran (BNT122, RO7198457)) clinical study for patients after complete resection of pancreatic ductal adenocarcinoma (PDAC) has shown promising results. PDAC is a type of tumor marked by reduced tumor mutational burden and an associated enhanced immunosuppressive tumor microenvironment, with a disease relapse rate and progression after surgery in about 80% of the patient population, placing it in an unmet medical need setting with very poor clinical outcomes. In the study, half of the patients exhibited a persistent and high-amplitude T cell response up to three years after administration, with an associated enlarged T cell","cbCaihvrrK0FmQAl","https://ap.wps.com/l/cbCaihvrrK0FmQAl","pdf",1100980,16,"English","# Abstract\n# Introduction\n## Breakthroughs in the Cancer Vaccine Field","[{\"question\":\"What is the main focus of the review on cancer vaccines?\",\"answer\":\"The review assesses the status and limitations of TSA-directed mRNA cancer vaccines and summarizes lessons relevant to developing TAA vaccines, including insights from checkpoint inhibitor studies.\"},{\"question\":\"Why are neoantigens both promising and challenging for personalized immunotherapy?\",\"answer\":\"Neoantigens can enable personalized immunotherapies because of their tumor specificity and immunogenicity, but research is still driven by the scarcity of immunogenic neoepitopes.\"},{\"question\":\"How do HERVs fit into alternative vaccine strategies mentioned in the review?\",\"answer\":\"Human endogenous retroviruses are presented as potential alternatives to tumor neoantigens due to high tumoral expression and their ability to elicit T cell reactivity and B cell responses linked to efficacy of existing immunotherapies.\"}]","Cancer Vaccines: Recent Insights and Future Directions | PDF",1790017061,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/548ba3a494570fcdb9dc24801e8cf4c3.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7bfdbb5c7c67e899e33ac62ffc63f666.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b58d8fb0345cc0405414f7f6bacec37.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c92fac60f72c405010fce60e66880dea.webp",980,1385]